Clinical Scorecard: Acute Post-Renal Obstruction Due to Bladder Metastasis from Gastric Cancer During Immunotherapy: A Case Study

At a Glance

Key Highlights

• Bladder metastasis from gastric cancer is rare and can be misdiagnosed during immunotherapy.
• Acute kidney injury and obstructive uropathy can occur despite stable primary gastric lesions.
• Cystoscopy and targeted biopsy are critical for distinguishing metastatic disease from immunotherapy-related toxicity.
• The patient experienced rapid disease progression despite initial treatment response.
• Histopathological examination confirmed the bladder lesion as metastatic poorly differentiated adenocarcinoma.

Guideline-Based Recommendations

Diagnosis

• Early cystoscopy and biopsy in patients with new urinary symptoms during immunotherapy.

Management

• Consideration of urinary diversion techniques such as nephrostomy in cases of obstructive uropathy.

Monitoring & Follow-up

• Regular assessment of renal function and tumor markers in patients receiving immunotherapy.

Risks

• Delayed diagnosis of metastatic disease may lead to irreversible renal damage.

Patient & Prescribing Data

Advanced gastric cancer patients receiving immunotherapy.

Combination of chemotherapy and PD-1 inhibitors may lead to atypical responses.

Clinical Best Practices

• Prompt evaluation of new urinary symptoms in patients on immunotherapy.
• Utilization of imaging and cystoscopy to assess urinary tract involvement.
• Multidisciplinary approach involving oncology and urology specialists.

Related Resources & Content

• Gastric Cancer Epidemiology
• Immunotherapy in Gastric Cancer